OncoMatch

OncoMatch/Clinical Trials/NCT07300241

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Is NCT07300241 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NEO-811 for clear cell renal cell carcinoma.

Phase 1RecruitingNeomorph, IncNCT07300241Data as of May 2026

Treatment: NEO-811 — The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study of NEO-811 for subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Renal Cell Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: standard therapies

Subjects must have progressed on or refused standard therapies

Lab requirements

Blood counts

Hemoglobin ≥10 g/dL, Absolute neutrophil count ≥1000 cells/µL, Platelet count ≥100,000/µL

Kidney function

Estimated glomerular filtration rate (eGFR) ≥60 mL/min

Liver function

AST and ALT ≤2.5 × ULN, or AST and ALT ≤5 × ULN for subjects with liver metastases; Total bilirubin ≤1.5 × ULN

Adequate hematologic, hepatic, and renal function defined as: Hemoglobin ≥10 g/dL, Absolute neutrophil count ≥1000 cells/µL, Platelet count ≥100,000/µL, AST and ALT ≤2.5 × ULN, or AST and ALT ≤5 × ULN for subjects with liver metastases, Total bilirubin ≤1.5 × ULN, Estimated glomerular filtration rate (eGFR) ≥60 mL/min.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • NEO-811 Grand Rapids Site · Grand Rapids, Michigan
  • NEO-811 Long Island Site · Lake Success, New York
  • NEO-811-101 NYC Site · New York, New York
  • NEO-811 South Carolina Site · Myrtle Beach, South Carolina
  • NEO-811 Dallas Site · Dallas, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify